New eye drops aim to soothe dry eye sufferers
NCT ID NCT04343287
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tested whether BRM421 eye drops can safely reduce the signs and symptoms of dry eye compared to a placebo. 220 adults with dry eye for at least 6 months received either the active drops or a placebo. The main outcomes were changes in corneal staining (eye surface damage) and patient-reported dryness after 14 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Andover Eye Associates
Andover, Massachusetts, 01810, United States
-
Eye Research Foundation
Newport Beach, California, 92663, United States
-
Midwest Cornea Associates, LLC
Indianapolis, Indiana, 46290, United States
-
Total Eye Care
Memphis, Tennessee, 38119, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BRM421 ophthalmic solution (eye drops)
What this could lead to
If successful, BRM421 could offer a new treatment option to reduce eye damage and dryness in people with dry eye syndrome.
What could go wrong
This is an early-to-mid stage trial with only 220 participants. The results may not show a meaningful benefit over placebo, and long-term safety is not yet established.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.